OpenDNA, a leading provider of advanced genetic testing solutions, has announced the launch of a new genetic test for obesity, now available as part of its comprehensive CardioRisk+ panel. This enhancement provides healthcare professionals with critical insights into an individual’s genetic predisposition to obesity, supporting more targeted and proactive preventive care.
CardioRisk+ is a state-of-the-art genetic test that evaluates an individual’s risk for a wide range of cardiometabolic conditions, including coronary artery disease, hypertension, hypercholesterolemia, type 2 diabetes – and now, obesity. By combining genetic and clinical insights, the panel helps clinicians deliver tailored interventions aimed at improving patient outcomes.
“The addition of obesity risk to our CardioRisk+ panel is a significant step forward in our mission to provide comprehensive genetic testing solutions,” said Dr. Eran Feldhay, Founder and CEO at OpenDNA. “By understanding an individual’s genetic predisposition to obesity, healthcare providers can work with their patients to implement early intervention strategies, such as dietary modifications, increased physical activity, and behavior counseling, to reduce their risk of developing obesity-related health complications. Furthermore, with the advent of GLP-1 weight loss drugs, we believe that in the future, CardioRisk+ obesity information will allow optimizing prescriptions to those that need it most.”
This addition reinforces OpenDNA’s goal of supporting physicians with real-world tools that translate genetic data into actionable clinical pathways. As obesity continues to drive significant healthcare burdens worldwide, this innovation offers timely and precise support for early intervention.
